Prevention of perinatal HIV transmission: Current status and future developments in anti-retroviral therapy

Drugs

Volumn 62, Issue 15, 2002, Pages 2213-2220

  Kourtis, Athena P ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DAPSONE; FOLIC ACID ANTAGONIST; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; PYRIMETHAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIMETHOPRIM; ZIDOVUDINE;

ANEMIA; BREAST FEEDING; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEVELOPING COUNTRY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FETUS MALFORMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABOR; LIVER DYSFUNCTION; MITOCHONDRION; NEUTROPENIA; NEWBORN INFECTION; PERINATAL INFECTION; PREGNANCY; PREMATURITY; RASH; REVIEW; SIDE EFFECT; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036033840     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262150-00004     Document Type: Review

References (57)

1. Mandelbrot L, LeChenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60
2. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343: 982-91
3. Kind C, Rudin C, Siegrist CA, et al.: Prevention of vertical HIV transmission: Additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-10
4. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-HIV in Africa, America and Europe: Results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 506-10
5. DeCock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. JAMA 2000; 283: 1175-82
6. Arbona SI, Melville SK, Hanson C, et al. Mother-to-child transmission of the human immunodeficiency virus in Texas. Pediatr Infect Dis 2001; 20: 602-6
7. DeCock K. Heterogeneity and Public Health in the Global HIV/AIDS Epidemic. Topics in HIV Medicine 2001; 9 (3): 15-9
8. Mofenson L. Antiretroviral therapy and interruption of HIV perinatal transmission. HIV and women and pregnancy. Immunol Allergy Clin North Am 1998; 18: 441-63
9. Newell ML. Mechanisms and timing of mother to child transmission of HIV-1. AIDS 1998; 12: 831-7
10. Bryson YY, Luzuriaga K, Sullivan JL, et al. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327: 1246-7
11. Kuhn L, Abrams EJ, Chincilla M, et al. New York City Perinatal HIV Transmission Collaborative Study Group. Sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period. AIDS 1996; 10: 1181-2
12. Kalish LA, Pitt J, Lews J, et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type I infection on the basis of age at first positive culture. J Infect Dis 1997; 175: 712-5
13. Shearer W, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type I. N Engl J Med 1997; 336: 1337-42
14. Steketee R, Abrams EJ, Thea DM, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infect Dis 1997; 176: 707-11
15. Kourtis AP, Bulterys M, Nesheim SR, et al. Understanding the timing of HIV transmission from mother-to-infant. JAMA 2001; 285: 709-12
16. Kuhn L, Abrams E, Matheson P, et al. Timing of maternal-infant HIV transmission: Association between intrapartum factors and early polymerase chain reaction results. AIDS 1997; 11: 429-35
17. Minkoff H, Burns D, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of HIV. Am J Obstet Gynecol 1995; 173: 585-9
18. Landesman SH, Kalish SA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type I from mother to child. N Engl J Med 1996; 334: 1617-23
19. European Collaborative Study. Cesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994; 343: 1464-7
20. The European Mode of Delivery Collaboration. Elective caesarian section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomized clinical trial. Lancet 1999; 353: 1035-9
21. DeRossi A, Ometto L, Mammano F, et al. Time course of antigenemia and seroconversion in infants with vertically acquired HIV-1 infection [letter]. AIDS 1993; 7 (11): 1528-9
22. Newell ML, Gibb DM. A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission. Drug Saf 1995; 12 (4): 274-82
23. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother to child HIV-1 transmission. Lancet 2000; 355: 2237-44
24. Connor EM, Sperling R, Gelber R, et al. Reduction of maternal-infant transmission of HIV type 1 with zidovudine treatment. N Engl J Med 1994; 311: 1173-80
25. Sperling RS, Shapiro ED, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of HIV-1 from mother to infant. N Engl J Med 1996; 335: 1621-9
26. Blanche S, Tartieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9
27. Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs. J Acquir Immune Defic Syndr 2000; 15: 261-8
28. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of HIV-1 in pediatric AIDS Clinical Trials Group. J Infect Dis 1998; 177: 557-64
29. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type-1 infected women and their newborns in the United States: Vertical transmission and clades. J Infect Dis 2001; 184: 1120-6
30. Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of HIV in a cohort of infected women and their infants. J Infect Dis 1996; 174 (6): 1207-11
31. Matheson PB, Abrams EJ, Thomas PA, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of HIV-1. J Infect Dis 1995; 172: 353-8
32. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15: 761-70
33. Shaffer N, Chuachoowong R, Mock P, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999; 353: 773-80
34. Wiktor S, Ekpini E, Karon J, et al. Short-course oral zidovudine for prevention of mother to child tranmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial. Lancet 1999; 353: 781-5
35. Dabis F, Msellati P, Meda N, et al. 6 Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double blind placebo controlled multicentre trial. Lancet 1999; 353: 786-92
36. Fiscus S, Adimora A, Schoenbach V, et al. Trends in HIV counseling, testing and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 1999; 180 (1): 99-105
37. Wade N, Birkhead G, Warren B, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-14
38. Wade NA, Birkhead GS, Warren BL, et al. Short courses of zidovudine and perinatal transmission of HIV [letter]. N Engl J Med 1999; 340: 1042-3
39. Bulterys M, Orloff S, Abrams E, et al. for the Perinatal AIDS Collaborative Transmission Study. Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: A prospective cohort study in 4 US cities [abstract no. 015]. Proceedings of the Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants: 1999 Sep 10-12; Montreal
40. Bardsley-Elliot A, Perry CM. Nevirapine: A review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs 2000; 5: 373-407
41. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354 (9181): 795-801
42. Moodley D. The SAINT trial: Nevirapine versus zidovudine + lamivudine in prevention of peripartum HIV transmission [abstract LbOr2]. Proceedings of the XIII International AIDS Conference; 2000 Jul 9-14: Durban, South Africa
43. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7
44. The PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (PETRA study): A randomised, double-blind, placebo-controlled trial. Lancet 2002; 359: 1178-86
45. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93
46. Clarke JR, Braganza R, Mirza A, et al.: Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59: 364-8
47. Helfgott AW, Eriksen N, Lewis S, et al. Highly active antiretroviral therapy for the prevention of perinatal HIV [abstract]. Am J Obstet Gynecol 2000 Jan; 182 (Pt 2): 100
48. Blattner W, Cooper E, Charurat M, et al. Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV-1 [abstract no. LbOr4]. Proceedings of the XIII International AIDS Conference; 2000 Jul 9-14; Durban, South Africa
49. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal transmission: A randomized trial. JAMA 2002; 288: 189-98
50. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-94
51. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. AIDS 1998; 12: F241-7
52. Shapiro D, Tuomala R, Samelson R, et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-infected women in 1998-1999 (PACTG 367) [abstract no. 664]. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 31-Feb 3; San Francisco (CA)
53. Jungmann EM, Mercey D, deRuiter A, et al.: Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001; 77: 441-3
54. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74 (4): 1767-74
55. Bulterys M, Lepage P. Mother-to-child transmission of HIV. Curr Opin Pediatr 1996; 10: 143-50
56. Centers for Disease Control and Prevention. U.S. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Weekly Rep 1998; 47 (RR-2): 1-29, [revisions on the website, November 3, 2000]
57. Boelart JR, Yaro S, Austustijns P, et al.: Chloroquine accumulates in breast-milk cells: Potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS 2001; 15: 2205-6